$Ionis Pharmaceuticals (IONS.US)$ Director KLEIN JOSEPH III sold 6,000 shares of common stock on May 3, 2024 at an average price of $42.7128 for a total value of $256.28K.
What is statement of changes in beneficial ownership of securities?
It is a requirement under federal securities laws that mandates individuals, including officers, directors, and those who hold more than 10% of any class of a company's securities (collectively known as "insiders"), to report their purchases, sales, and holdings of their company's securities by submitting Forms 3, 4, and 5.